PubMed Health⌕ Search

PubMed · 10706321

Pulse pressure and cardiovascular risk.

Abstract

Numerous studies have shown that increases in diastolic (DBP) and systolic (SBP) blood pressure are positively associated with cardiac events. Since DBP typically varies by smaller amounts, it has historically been the blood pressure value used most often to assess the risk of cardiovascular disease. Further studies have indicated, however, that SBP continues to increase proportionally with age, while DBP levels off. New data have emerged which suggest that DBP can no longer be valued as a reliable predictor of cardiovascular events and may even be diagnostically misleading. Normal levels of DBP can be indicative of a combination of an increase in peripheral vascular resistance (which elevates DBP) with an increase in arterial stiffening (which decreases DBP). These two phenomena 'cancel' each other out; the underlying risk factors are disguised by the apparent normalcy of the DBP reading. DBP is even less of an indicator in older adults, where the prevailing form of hypertension is isolated systolic hypertension and the most common cause is large-artery stiffness. Since arterial stiffening causes SBP to increase and DBP to decrease, the gap between the two, pulse pressure (PP), may be the best predictor of cardiac events for all the blood pressure values. Several studies have confirmed that subjects with the widest PP have the greatest risk of mortality. Pulse pressure has also been observed to be a significant and independent indicator of myocardial infarction. Furthermore, compelling evidence has emerged that PP is a strong indicator of cardiovascular risk even among normotensive individuals.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Benetos. 1999. Pulse pressure and cardiovascular risk.. https://pubmed.ncbi.nlm.nih.gov/10706321/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Tree-structured gatekeeping tests in clinical trials with hierarchically ordered multiple objectives.

This paper discusses a new class of multiple testing procedures, tree-structured gatekeeping procedures, with clinical trial applications. These procedures arise in clinical trials with hierarchically ordered multiple objectives, for example, in the context of multiple dose-control tests with logical restrictions or analysis of multiple endpoints. The proposed approach is based on the principle of closed testing and generalizes the serial and parallel gatekeeping approaches developed by Westfall and Krishen (J. Statist. Planning Infer. 2001; 99:25-41) and Dmitrienko et al. (Statist. Med. 2003; 22:2387-2400). The proposed testing methodology is illustrated using a clinical trial with multiple endpoints (primary, secondary and tertiary) and multiple objectives (superiority and non-inferiority testing) as well as a dose-finding trial with multiple endpoints.

Antihypertensive Agents↗

Bayesian analysis of latent variable models with non-ignorable missing outcomes from exponential family.

To provide a comprehensive framework for analysing complex non-normal medical and biological data, we propose a Bayesian approach for a non-linear latent variable model with covariates, and non-ignorable missing data, under the exponential family of distributions. The non-ignorable missing mechanism is defined via a logistic regression model. Based on conjugate prior distributions, full conditional distributions for the implementation of Markov chain Monte Carlo methods in simulating observations from the joint posterior distribution are derived. These observations are used in computing the Bayesian estimates, as well as in implementing a path sampling procedure to evaluate the Bayes factor for model comparison. The proposed methods are illustrated using real data from a study on the non-adherence of hypertension patients.

Antihypertensive Agents↗

Revisiting the relation between change and initial value: a review and evaluation.

The relation between initial disease status and subsequent change following treatment has attracted great interest in clinical research. However, statisticians have repeatedly warned against correlating/regressing change with baseline due to two methodological concerns known as mathematical coupling and regression to the mean. Oldham's method and Blomqvist's formula are the two most often adopted methods to rectify these problems. The aims of this article are to review briefly the proposed solutions in the statistical and psychological literature, and to clarify the popular misconception that Blomqvist's formula is superior to Oldham's method. We argue that this misconception is due to a failure to recognize that the heterogeneity of individual responses to treatment is a source of regression to the mean in the analysis of the relation between change and initial value. Furthermore, we demonstrate how each method actually answers different research questions, and how confusion arises when this is not always understood.

Antihypertensive Agents↗